Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

SAN DIEGO, May 2, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2013.

During the first quarter of 2013, Cadence reported net product revenue from sales of OFIRMEV® (acetaminophen) injection of $23.6 million, which includes the one-time recognition of $2.6 million in deferred revenue on previously shipped product. Consistent with other companies with products at this stage of commercialization, and based upon its determination it had obtained sufficient product return history to reasonably estimate future wholesaler returns, beginning on January 1, 2013, the company began to recognize revenue at the time that the product is sold to a wholesaler.

Excluding the recognition of $2.6 million in previously deferred revenue, net product revenue for the first quarter of 2013 was $21.0 million, which represents an increase of more than 160% from the $8.0 million in net product revenue recognized for the first quarter of 2012, and an increase of 23% from the $17.1 million recognized for the fourth quarter of 2012.

Highlights for the first quarter of 2013 included:

  • The gross margin on sales of OFIRMEV was 65% for the first quarter of 2013, as compared to 47% for the first quarter of 2012.
  • As of March 31, 2013, the company had over 4,000 unique customer accounts, an increase of nearly 50% from the first quarter of 2012.
  • The average order size by end-user customers increased 28% during the first quarter of 2013 as compared to the first quarter of 2012.
  • On March 12, 2013, the company announced that the Department of Veterans Affairs added OFIRMEV to the VA Natio
    '/>"/>

  • SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
    2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
    3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
    4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
    5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
    6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
    7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
    8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
    9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
    10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
    11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con ... europeo in occasione di Hi Europe 2014 (dal 2 ... Si tratta della curcumina con la maggiore biodisponibilità ... cristalli) e ingredienti approvati dalle norme europee. ... della pianta curcumina ( Curcuma longa ) che è ...
    (Date:11/24/2014)... , Nov. 24, 2014  IGI Laboratories, Inc. ... based specialty generic pharmaceutical company, today announced it ... to the U.S. Food and Drug Administration (FDA), which ... 2014 to seven, with eighteen submissions now pending at ... President and CEO of the Company, commented, "Our team ...
    (Date:11/24/2014)... 2014  Last week, Representatives Gus Bilirakis ... took a bold bipartisan step on behalf of ... Act. Original co-sponsors of the legislation include Representatives ... incentivize drug makers and innovators to "repurpose" major ... cancers, which opens the door to the development ...
    (Date:11/24/2014)...   First published ... Elsevier , a world-leading provider of scientific, technical ... the launch of the latest title in the Current ... Food Science . Current ... new platform to keep up-to-date with the expanding volume of ...
    Breaking Biology Technology:La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
    ... Biosciences, Inc.,(Nasdaq: RDEA ) today announced that preclinical data will ... Digestive Disease Week (DDW) 2008 in San Diego., The ... Date/Time: Tuesday, May 20, 2008 at 3:30 p.m. Pacific Time ... Selective MEK Inhibitor Ameliorates Murine ...
    ... CHICAGO, May 14 Last month a lawsuit ... of Davenport,Iowa resident, Mark Scott who suffered the tragic ... The complaint was filed On April 1, 2008 in,the ... and alleges that,Melissa Scott,s untimely death was caused by ...
    ... Augments Senior Management Team with Recent Strategic Hires ... ... May 14 Triple-S,Management Corporation (NYSE: GTS ) today announced that ... for the Children,s Oncology Group and,the Dana Farber Acute Lymphoblastic Leukemia Consortium, ...
    Cached Biology Technology:Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008 2Iowa Resident Dies After Using Contaminated Blood Thinner 2Iowa Resident Dies After Using Contaminated Blood Thinner 3Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director 2
    (Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
    (Date:11/10/2014)... U.S. store shelves in early 2010, and people have ... packets can be tossed into a washing machine without ... The convenience, though, has come with risks for young ... Children,s Hospital found that from 2012 through 2013, U.S. ... than 6 years of age swallowing, inhaling, or otherwise ...
    (Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
    Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3
    ... Understanding the structure, function, and development of the ... the great scientific challenges of our time. The ... to create unique databases and analytical tools for ... them to brain research and linking them with ...
    ... embedded with bright, light-emitting molecules have enabled researchers ... below the skin surface using only infrared light. ... based at the University of Pennsylvania and the ... porphyrins within the surface of a polymersome, a ...
    ... Although new HIV treatments have drastically reduced the ... remains a health threat in many developing countries. ... sarcoma ?a cancer-like viral disease traditionally associated with ... Howard Hughes Medical Institute (HHMI) investigator, and HHMI ...
    Cached Biology News:Wiley announces publication of Databasing the Brain 2Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin 2How an AIDS-Related Cancer Unleashes Inflammation 2How an AIDS-Related Cancer Unleashes Inflammation 3
    Request Info...
    Purified anti-eIF-4E...
    Peptide-affinity Purified Polyclonal Antibody to SMAD7 Peptide with sequence SSCPCWLEVIFNSR, from C Terminus of the protein sequence according to NP_005895....
    Purified anti-PXR...
    Biology Products: